婴儿肉毒中毒。

Ashley Garispe, Steven Cherry
{"title":"婴儿肉毒中毒。","authors":"Ashley Garispe,&nbsp;Steven Cherry","doi":"10.21980/J88350","DOIUrl":null,"url":null,"abstract":"<p><strong>Audience: </strong>This oral board case is appropriate for emergency medicine residents and medical students (with senior resident assistance) on emergency medicine rotation.</p><p><strong>Introduction: </strong>Although a somewhat rare disease, infant botulism is a true pediatric emergency that carried a 90% rate of mortality prior to the development of an antitoxin.1 While botulism infections can be iatrogenic, foodborne, or involve infected wounds, infant botulism remains the most common presentation of this disease and accounts for approximately 70% of new cases annually.2 Caused by <i>Clostridium botulinum</i>, the inactive spores are ingested by the infant and germinate in the large intestine.3,4 The resulting neurotoxin prevents the release of acetylcholine at the presynaptic membrane which results in flaccid paralysis. Classically, the bulbar musculature is affected before somatic muscular, which results in the typical presentation of \"descending paralysis.\"2,5 While confirmatory testing is important, it is often delayed by more than 24 hours, making both clinical recognition and implementation of treatment before confirmatory testing of vital importance.6,7 Treatment consists of providing airway, nutritional, and hydration support in addition to administering botulinum-specific antitoxin.8,9 While patients over the age of 12 months are treated with equine botulinum antitoxin, the Food and Drug Administration (FDA) has approved a human-derived immunoglobulin treatment, Botulism Immune Globulin Intravenous (BIG-IV, ie, \"Baby BIG\") for pediatric patients less than 12 months of age.1,2,6 Ordering BIG-IV is a complex and multidisciplinary process, requiring the treating physician to discuss any suspicious case with the Infant Botulism Treatment and Prevention Program (IBTPP) which is a branch of the California Department of Public Health.6 With early recognition and implementation of treatment, most infants will make a full recovery.</p><p><strong>Educational objectives: </strong>At the end of this oral board session, examinees will: 1) demonstrate an ability to obtain a complete pediatric medical history, 2) perform an appropriate physical exam on a pediatric patient, 3) investigate a broad differential diagnosis for neuromuscular weakness in a pediatric patient, 4) recognize the classic presentation of infant botulism and implement treatment with botulinum specific antitoxin before confirmatory testing, 5) recognize impending airway failure and intubate the pediatric patient with appropriately dosed medications and ET tube size, and 6) demonstrate effective communication with healthcare team members and parents.</p><p><strong>Educational methods: </strong>This oral board case followed the standard American Board of Emergency Medicine-style case in a tertiary care hospital with access to all specialists and resources needed. This case was tested using 12 resident volunteers ranging from PGY 1-2 in an ACGME (Accreditation Council for Graduate Medical Education) accredited emergency medicine residency program. Learners were debriefed immediately after the case and were given the opportunity to provide feedback.</p><p><strong>Research methods: </strong>The learners participating in the oral board case provided immediate feedback both by verbal discussion and via a written survey requiring them to rate the efficacy of the exercise. The efficacy of the educational content was assessed by comparing scoring measures of the ACGME core competencies across all learners based on post graduate year (PGY). Scoring measures were determined using a scale from 1-8, with 1-4 being unacceptable performance and 5-8 being acceptable. Efficacy required full completion of the oral board case by the residents as well as a debriefing session during which key educational concepts were discussed.</p><p><strong>Results: </strong>The practice oral board candidates consisted of 7 PGY1 and 5 PGY2 level residents. The average score of participating residents for each training level was PGY1: 4.5 and PGY2: 5.7. All except for 2 PGY2 residents missed at least one critical action with the majority of PGY1 residents missing more than one critical action for the case. All participating residents rated the educational value of the case as 4.75 (1-5 Likert scale, with 5 being excellent).</p><p><strong>Discussion: </strong>The educational content of this oral board case and debriefing session were effective for teaching the presentation, evaluation, and appropriate management of infant botulism. Infant botulism is a true pediatric emergency and prompt recognition and treatment is imperative in order to decrease mortality. While mortality was approximately 90% one hundred years ago, today infant botulism carries a much better prognosis due to the advent of antitoxin treatment with a mortality closer to 15%.1 This case highlights several classic physical exam findings including bulbar findings in addition to somatic weakness. Additionally, this case requires definitive airway management with endotracheal intubation, which is true for approximately 50% of infants with botulism.1 While a stool culture or direct toxin assay of the gastric contents, serum, or stool should be performed to confirm the diagnosis, these tests are often performed by the state health department or the Centers for Disease Control (CDC) and often take up to five days to result, during which time the patient will continue to deteriorate. Therefore, the treating physician should seek emergent consultation with the IBTPP to help facilitate the multidisciplinary decision to initiate treatment with human-derived anti-botulinum toxin antibodies.6 If the IBTPP deems that infant botulism is highly suspected based on the history and physical exam, then appropriate treatment should not be delayed and BIG-IV should be administered.6, 7 With early recognition and implementation of treatment, most infants will make a full recovery within several months to a year. Upon discharge, patients will likely require outpatient neurology follow-up in addition to physical therapy to aid in recovery. Because infant botulism is a true pediatric emergency with potentially high mortality, reaching the appropriate diagnosis expeditiously will allow the emergency physician to communicate effectively with worried parents regarding the disease progression and facilitate correct treatment early in order to prevent significant sequela.</p><p><strong>Topics: </strong>Pediatric weakness, pediatric neurotoxin, infant botulism, neuromuscular weakness.</p>","PeriodicalId":73721,"journal":{"name":"Journal of education & teaching in emergency medicine","volume":"8 3","pages":"O33-O60"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414984/pdf/","citationCount":"0","resultStr":"{\"title\":\"Infant Botulism.\",\"authors\":\"Ashley Garispe,&nbsp;Steven Cherry\",\"doi\":\"10.21980/J88350\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Audience: </strong>This oral board case is appropriate for emergency medicine residents and medical students (with senior resident assistance) on emergency medicine rotation.</p><p><strong>Introduction: </strong>Although a somewhat rare disease, infant botulism is a true pediatric emergency that carried a 90% rate of mortality prior to the development of an antitoxin.1 While botulism infections can be iatrogenic, foodborne, or involve infected wounds, infant botulism remains the most common presentation of this disease and accounts for approximately 70% of new cases annually.2 Caused by <i>Clostridium botulinum</i>, the inactive spores are ingested by the infant and germinate in the large intestine.3,4 The resulting neurotoxin prevents the release of acetylcholine at the presynaptic membrane which results in flaccid paralysis. Classically, the bulbar musculature is affected before somatic muscular, which results in the typical presentation of \\\"descending paralysis.\\\"2,5 While confirmatory testing is important, it is often delayed by more than 24 hours, making both clinical recognition and implementation of treatment before confirmatory testing of vital importance.6,7 Treatment consists of providing airway, nutritional, and hydration support in addition to administering botulinum-specific antitoxin.8,9 While patients over the age of 12 months are treated with equine botulinum antitoxin, the Food and Drug Administration (FDA) has approved a human-derived immunoglobulin treatment, Botulism Immune Globulin Intravenous (BIG-IV, ie, \\\"Baby BIG\\\") for pediatric patients less than 12 months of age.1,2,6 Ordering BIG-IV is a complex and multidisciplinary process, requiring the treating physician to discuss any suspicious case with the Infant Botulism Treatment and Prevention Program (IBTPP) which is a branch of the California Department of Public Health.6 With early recognition and implementation of treatment, most infants will make a full recovery.</p><p><strong>Educational objectives: </strong>At the end of this oral board session, examinees will: 1) demonstrate an ability to obtain a complete pediatric medical history, 2) perform an appropriate physical exam on a pediatric patient, 3) investigate a broad differential diagnosis for neuromuscular weakness in a pediatric patient, 4) recognize the classic presentation of infant botulism and implement treatment with botulinum specific antitoxin before confirmatory testing, 5) recognize impending airway failure and intubate the pediatric patient with appropriately dosed medications and ET tube size, and 6) demonstrate effective communication with healthcare team members and parents.</p><p><strong>Educational methods: </strong>This oral board case followed the standard American Board of Emergency Medicine-style case in a tertiary care hospital with access to all specialists and resources needed. This case was tested using 12 resident volunteers ranging from PGY 1-2 in an ACGME (Accreditation Council for Graduate Medical Education) accredited emergency medicine residency program. Learners were debriefed immediately after the case and were given the opportunity to provide feedback.</p><p><strong>Research methods: </strong>The learners participating in the oral board case provided immediate feedback both by verbal discussion and via a written survey requiring them to rate the efficacy of the exercise. The efficacy of the educational content was assessed by comparing scoring measures of the ACGME core competencies across all learners based on post graduate year (PGY). Scoring measures were determined using a scale from 1-8, with 1-4 being unacceptable performance and 5-8 being acceptable. Efficacy required full completion of the oral board case by the residents as well as a debriefing session during which key educational concepts were discussed.</p><p><strong>Results: </strong>The practice oral board candidates consisted of 7 PGY1 and 5 PGY2 level residents. The average score of participating residents for each training level was PGY1: 4.5 and PGY2: 5.7. All except for 2 PGY2 residents missed at least one critical action with the majority of PGY1 residents missing more than one critical action for the case. All participating residents rated the educational value of the case as 4.75 (1-5 Likert scale, with 5 being excellent).</p><p><strong>Discussion: </strong>The educational content of this oral board case and debriefing session were effective for teaching the presentation, evaluation, and appropriate management of infant botulism. Infant botulism is a true pediatric emergency and prompt recognition and treatment is imperative in order to decrease mortality. While mortality was approximately 90% one hundred years ago, today infant botulism carries a much better prognosis due to the advent of antitoxin treatment with a mortality closer to 15%.1 This case highlights several classic physical exam findings including bulbar findings in addition to somatic weakness. Additionally, this case requires definitive airway management with endotracheal intubation, which is true for approximately 50% of infants with botulism.1 While a stool culture or direct toxin assay of the gastric contents, serum, or stool should be performed to confirm the diagnosis, these tests are often performed by the state health department or the Centers for Disease Control (CDC) and often take up to five days to result, during which time the patient will continue to deteriorate. Therefore, the treating physician should seek emergent consultation with the IBTPP to help facilitate the multidisciplinary decision to initiate treatment with human-derived anti-botulinum toxin antibodies.6 If the IBTPP deems that infant botulism is highly suspected based on the history and physical exam, then appropriate treatment should not be delayed and BIG-IV should be administered.6, 7 With early recognition and implementation of treatment, most infants will make a full recovery within several months to a year. Upon discharge, patients will likely require outpatient neurology follow-up in addition to physical therapy to aid in recovery. Because infant botulism is a true pediatric emergency with potentially high mortality, reaching the appropriate diagnosis expeditiously will allow the emergency physician to communicate effectively with worried parents regarding the disease progression and facilitate correct treatment early in order to prevent significant sequela.</p><p><strong>Topics: </strong>Pediatric weakness, pediatric neurotoxin, infant botulism, neuromuscular weakness.</p>\",\"PeriodicalId\":73721,\"journal\":{\"name\":\"Journal of education & teaching in emergency medicine\",\"volume\":\"8 3\",\"pages\":\"O33-O60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414984/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of education & teaching in emergency medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21980/J88350\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of education & teaching in emergency medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21980/J88350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

听众:这个口服药案例适合急诊医学住院医师和急诊医学轮转的医学生(在高级住院医师的协助下)。导读:虽然婴儿肉毒杆菌中毒是一种罕见的疾病,但它是一种真正的儿科急症,在抗毒素产生之前,其死亡率高达90%虽然肉毒杆菌感染可能是医源性的、食源性的或涉及伤口感染,但婴儿肉毒杆菌中毒仍然是这种疾病最常见的表现,每年约占新病例的70%由肉毒杆菌引起的无活性孢子被婴儿摄入并在大肠中发芽。由此产生的神经毒素阻止乙酰胆碱在突触前膜的释放,从而导致弛缓性麻痹。通常,球肌比躯体肌受影响更早,这导致了典型的“下行性麻痹”。2,5虽然确证性检测很重要,但往往延迟超过24小时,这使得在确证性检测之前的临床识别和治疗实施都至关重要。6,7除给予肉毒杆菌特异性抗毒素外,治疗包括提供气道、营养和水化支持。8,9虽然12个月以上的患者接受马肉毒杆菌抗毒素治疗,但美国食品和药物管理局(FDA)已经批准了一种人类来源的免疫球蛋白治疗,肉毒杆菌免疫球蛋白静脉注射(BIG- iv,即“Baby BIG”),用于12个月以下的儿科患者。订购BIG-IV是一个复杂的多学科过程,需要治疗医生与婴儿肉毒杆菌中毒治疗和预防计划(IBTPP)讨论任何可疑病例,该计划是加州公共卫生部的一个分支。6通过早期识别和实施治疗,大多数婴儿将完全康复。教育目标:在口试结束时,考生将:1)有能力获得完整的儿童病史,2)对儿童患者进行适当的体格检查,3)对儿童患者的神经肌肉无力进行广泛的鉴别诊断,4)识别婴儿肉毒杆菌中毒的典型表现,并在确认性检查之前使用肉毒杆菌特异性抗毒素进行治疗。5)认识到即将发生的气道衰竭,并为儿科患者插管适当剂量的药物和适当大小的ET管;6)与医疗团队成员和家长进行有效的沟通。教育方法:本病例遵循三级护理医院的美国急诊医学委员会标准病例,可获得所需的所有专家和资源。本病例使用12名住院医师志愿者进行测试,他们来自ACGME(研究生医学教育认证委员会)认可的急诊医学住院医师项目,年龄从PGY 1-2。学员在案例结束后立即听取了情况汇报,并有机会提供反馈。研究方法:参与口头黑板案例的学习者通过口头讨论和书面调查提供即时反馈,要求他们对练习的效果进行评估。通过比较基于研究生年(PGY)的所有学习者的ACGME核心能力得分指标来评估教育内容的有效性。评分方法采用1-8的评分标准,1-4为不可接受,5-8为可接受。要达到效果,住院医生必须完成口头陈述,并进行汇报,讨论关键的教育概念。结果:PGY1级住院医师7名,PGY2级住院医师5名。各培训级别住院医师的平均得分为PGY1: 4.5, PGY2: 5.7。除2名PGY2居民外,所有居民都错过了至少一个关键动作,而大多数PGY1居民都错过了一个以上的关键动作。所有参与的居民对该案例的教育价值评价为4.75(1-5李克特量表,5为优秀)。讨论:本案例的教育内容和汇报会议对婴儿肉毒杆菌中毒的介绍、评估和适当管理的教学是有效的。婴儿肉毒杆菌中毒是一种真正的儿科急症,为了降低死亡率,及时识别和治疗是必不可少的。100年前,婴儿肉毒杆菌中毒的死亡率约为90%,而今天,由于抗毒素治疗的出现,婴儿肉毒杆菌中毒的预后要好得多,死亡率接近15%本病例强调了几个经典的体检结果,包括球的发现和躯体无力。此外,这种情况需要通过气管内插管进行明确的气道管理,这对于大约50%的肉毒杆菌中毒婴儿是正确的。 虽然需要对胃内容物、血清或粪便进行粪便培养或直接毒素测定以确认诊断,但这些检查通常由州卫生部门或疾病控制中心(CDC)进行,通常需要长达5天的时间才能得出结果,在此期间患者将继续恶化。因此,治疗医师应寻求IBTPP的紧急会诊,以帮助多学科决定是否开始使用人源性抗肉毒杆菌毒素抗体进行治疗如果IBTPP根据病史和体格检查认为婴儿肉毒杆菌中毒高度可疑,则不应延误适当的治疗,并应给予BIG-IV。如果及早发现并实施治疗,大多数婴儿将在几个月到一年内完全康复。出院后,除了物理治疗外,患者可能需要门诊神经病学随访以帮助康复。由于婴儿肉毒杆菌中毒是一种真正的儿科急症,具有潜在的高死亡率,迅速得到适当的诊断将使急诊医生能够有效地与担心疾病进展的父母沟通,并促进早期正确治疗,以防止严重的后遗症。主题:小儿无力,小儿神经毒素,婴儿肉毒杆菌中毒,神经肌肉无力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Infant Botulism.

Infant Botulism.

Infant Botulism.

Infant Botulism.

Audience: This oral board case is appropriate for emergency medicine residents and medical students (with senior resident assistance) on emergency medicine rotation.

Introduction: Although a somewhat rare disease, infant botulism is a true pediatric emergency that carried a 90% rate of mortality prior to the development of an antitoxin.1 While botulism infections can be iatrogenic, foodborne, or involve infected wounds, infant botulism remains the most common presentation of this disease and accounts for approximately 70% of new cases annually.2 Caused by Clostridium botulinum, the inactive spores are ingested by the infant and germinate in the large intestine.3,4 The resulting neurotoxin prevents the release of acetylcholine at the presynaptic membrane which results in flaccid paralysis. Classically, the bulbar musculature is affected before somatic muscular, which results in the typical presentation of "descending paralysis."2,5 While confirmatory testing is important, it is often delayed by more than 24 hours, making both clinical recognition and implementation of treatment before confirmatory testing of vital importance.6,7 Treatment consists of providing airway, nutritional, and hydration support in addition to administering botulinum-specific antitoxin.8,9 While patients over the age of 12 months are treated with equine botulinum antitoxin, the Food and Drug Administration (FDA) has approved a human-derived immunoglobulin treatment, Botulism Immune Globulin Intravenous (BIG-IV, ie, "Baby BIG") for pediatric patients less than 12 months of age.1,2,6 Ordering BIG-IV is a complex and multidisciplinary process, requiring the treating physician to discuss any suspicious case with the Infant Botulism Treatment and Prevention Program (IBTPP) which is a branch of the California Department of Public Health.6 With early recognition and implementation of treatment, most infants will make a full recovery.

Educational objectives: At the end of this oral board session, examinees will: 1) demonstrate an ability to obtain a complete pediatric medical history, 2) perform an appropriate physical exam on a pediatric patient, 3) investigate a broad differential diagnosis for neuromuscular weakness in a pediatric patient, 4) recognize the classic presentation of infant botulism and implement treatment with botulinum specific antitoxin before confirmatory testing, 5) recognize impending airway failure and intubate the pediatric patient with appropriately dosed medications and ET tube size, and 6) demonstrate effective communication with healthcare team members and parents.

Educational methods: This oral board case followed the standard American Board of Emergency Medicine-style case in a tertiary care hospital with access to all specialists and resources needed. This case was tested using 12 resident volunteers ranging from PGY 1-2 in an ACGME (Accreditation Council for Graduate Medical Education) accredited emergency medicine residency program. Learners were debriefed immediately after the case and were given the opportunity to provide feedback.

Research methods: The learners participating in the oral board case provided immediate feedback both by verbal discussion and via a written survey requiring them to rate the efficacy of the exercise. The efficacy of the educational content was assessed by comparing scoring measures of the ACGME core competencies across all learners based on post graduate year (PGY). Scoring measures were determined using a scale from 1-8, with 1-4 being unacceptable performance and 5-8 being acceptable. Efficacy required full completion of the oral board case by the residents as well as a debriefing session during which key educational concepts were discussed.

Results: The practice oral board candidates consisted of 7 PGY1 and 5 PGY2 level residents. The average score of participating residents for each training level was PGY1: 4.5 and PGY2: 5.7. All except for 2 PGY2 residents missed at least one critical action with the majority of PGY1 residents missing more than one critical action for the case. All participating residents rated the educational value of the case as 4.75 (1-5 Likert scale, with 5 being excellent).

Discussion: The educational content of this oral board case and debriefing session were effective for teaching the presentation, evaluation, and appropriate management of infant botulism. Infant botulism is a true pediatric emergency and prompt recognition and treatment is imperative in order to decrease mortality. While mortality was approximately 90% one hundred years ago, today infant botulism carries a much better prognosis due to the advent of antitoxin treatment with a mortality closer to 15%.1 This case highlights several classic physical exam findings including bulbar findings in addition to somatic weakness. Additionally, this case requires definitive airway management with endotracheal intubation, which is true for approximately 50% of infants with botulism.1 While a stool culture or direct toxin assay of the gastric contents, serum, or stool should be performed to confirm the diagnosis, these tests are often performed by the state health department or the Centers for Disease Control (CDC) and often take up to five days to result, during which time the patient will continue to deteriorate. Therefore, the treating physician should seek emergent consultation with the IBTPP to help facilitate the multidisciplinary decision to initiate treatment with human-derived anti-botulinum toxin antibodies.6 If the IBTPP deems that infant botulism is highly suspected based on the history and physical exam, then appropriate treatment should not be delayed and BIG-IV should be administered.6, 7 With early recognition and implementation of treatment, most infants will make a full recovery within several months to a year. Upon discharge, patients will likely require outpatient neurology follow-up in addition to physical therapy to aid in recovery. Because infant botulism is a true pediatric emergency with potentially high mortality, reaching the appropriate diagnosis expeditiously will allow the emergency physician to communicate effectively with worried parents regarding the disease progression and facilitate correct treatment early in order to prevent significant sequela.

Topics: Pediatric weakness, pediatric neurotoxin, infant botulism, neuromuscular weakness.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信